Application of USC ∗ PACK clinical programs to vancomycin in neutropenic patients

Kergueris, Marie‐France; Normand, Y. Le; Jahan, P.; Milpied, Noël

doi:10.1016/0020-7101(94)90114-7

Cited by 6 publications

(3 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Discussionmentioning

confidence: 99%

“…The phenomenon of insufficient concentration of vancomycin is commonly found in patients with hematological diseases. Kergueris reported that the vancomycin elimination rate, which is constant in patients with neutropenia, was higher than that in the general population and had no significant correlation with serum creatinine and urine volume in such patients (Kergueris et al., 1994 ). Michiel B. Haeseker's study revealed that the clearance rate of vancomycin in patients with neutropenia was significantly higher than that in patients without neutropenia (CL = 67 ± 26 ml/min vs. CL = 50 ± 22 ml/min).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical application of vancomycin population pharmacokinetics model in patients with hematological diseases and neutropenia

Lin

Huang

et al. 2021

Biopharm & Drug Disp

View full text Add to dashboard Cite

To explore the clinical application of a population pharmacokinetics (PPK) model of vancomycin in patients with hematological diseases and neutropenia. Patients with hematological diseases and neutropenia were included in the PPK model study.Nonlinear mixed effect modeling approach (NONMEM) was used for model establishment. Monte Carlo simulation was carried out. A total of 74 patients were divided into model group and non-model group for clinical application research. The model group was given the initial dose of 1g q8h, and the non-model group was given 1g q12h as an empiric initial dosage. The follow-up dose adjustments were made according to the concentration results. This two-compartment model showed good stability and accuracy. The first trough concentration (C 0 ) and the compliance rate of the first C 0 were much higher in the model group than that in the non-model group (14.30 � 4.73 μg/ml and 59.38% vs. 8.02 � 2.61 μg/ml, 35.71%). Less patients needed dose adjustments and fewer adjustment times in the model group than those in the non-model group (12.50% and 0.13 � 0.34 times vs. 50.00% and 0.61 � 0.66 times). This suggested that for those patients who had a Creatinine clearance rate (CLCR) ≥ 90 ml/min/1.73 m 2 , the initial dose of 1g q8h may help to reach the target C 0 (10∼20 μg/ml) quickly. It also helped to reduce the times and number of patients who need dose adjustments. Our PPK model of vancomycin in patients with hematologic diseases and neutropenia can be used to shorten the time to reach the target concentration and reduce the number of dose adjustments.Clinical trial registration: Not applicable (Retrospective study).

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Clinical application of vancomycin population pharmacokinetics model in patients with hematological diseases and neutropenia

Lin

Huang

et al. 2021

Biopharm & Drug Disp

View full text Add to dashboard Cite

show abstract

“…The phenomenon of insu cient concentration of vancomycin is commonly found in patients with hematological diseases. Kergueris reported that the vancomycin elimination rate, which is constant in patients with neutropenia, was higher than that in the general population and had no signi cant correlation with serum creatinine and urine volume in such patients [15]. Michiel B. haeseker's study revealed that the clearance rate of vancomycin in patients with neutropenia was signi cantly higher than that in patients without neutropenia (CL = 67 ± 26ml/min vs. CL = 50 ± 22ml/min).…”

Section: Discussionmentioning

confidence: 98%

Clinical Application of Vancomycin PPK Model in Patients with Neutropenia

Huang

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: To explore the clinical application of a population pharmacokinetics (PPK) model of vancomycin in patients with hematological diseases who developed neutropenia.Methods: Patients with neutropenia treated at the Department of Hematology in our hospital were included in the PPK model study. A nonlinear mixed effect modeling approach (NONMEM) was used to establish the PPK model of those patients. Monte Carlo simulation was also carried out. A total of 64 patients were divided into model group and non-model group for clinical application research. The model group was given the first dose of 1g q8h, and the non-model group was given 1g q12h as the empiric therapy; the follow-up dose adjustment was made according to the concentration results.Results: This two-compartment model showed good stability and accuracy. The average concentrations in the model group and the non-model group were significantly different, i.e., 13.45±4.07 μg/ml, 60.71% reaching the target concentration vs. 9.85±3.76 μg/ml, 27.78% reaching the target concentration, respectively (all P<0.05). This suggested that for patients with neutropenia and CLCR≥90 ml/min/1.73m2, the first dose of 1g q8h may help to reach the target concentration as soon as possible.Conclusions: Our PPK model of vancomycin in patients with hematologic diseases who developed neutropenia can be used to realize the individualized application of vancomycin in this population.

show abstract

What Can We Learn from Studies Comparing Linezolid with Vancomycin in Neutropenic Patients When Vancomycin Dosages Are Not Optimized?

Tattevin

Camus

2006

Clinical Infectious Diseases

View full text Add to dashboard Cite

Application of USC ∗ PACK clinical programs to vancomycin in neutropenic patients

Cited by 6 publications

References 6 publications

Clinical application of vancomycin population pharmacokinetics model in patients with hematological diseases and neutropenia

Clinical application of vancomycin population pharmacokinetics model in patients with hematological diseases and neutropenia

Clinical Application of Vancomycin PPK Model in Patients with Neutropenia

What Can We Learn from Studies Comparing Linezolid with Vancomycin in Neutropenic Patients When Vancomycin Dosages Are Not Optimized?

Contact Info

Product

Resources

About